I-Mab (NASDAQ:IMAB) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of I-Mab (NASDAQ:IMAB) in a research note published on Thursday morning, Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock.

I-Mab Trading Up 0.9 %

Shares of NASDAQ IMAB opened at $1.13 on Thursday. The firm’s 50-day moving average price is $1.37 and its 200-day moving average price is $1.64. I-Mab has a 1-year low of $0.99 and a 1-year high of $2.54.

I-Mab (NASDAQ:IMAB) last posted its quarterly earnings results on Wednesday, August 28th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.44. On average, analysts predict that I-Mab will post -0.38 earnings per share for the current fiscal year.

Institutional Trading of I-Mab

A hedge fund recently bought a new stake in I-Mab stock. Bank of Montreal Can acquired a new stake in shares of I-Mab (NASDAQ:IMAB) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 244,875 shares of the company’s stock, valued at approximately $453,000. Bank of Montreal Can owned about 0.30% of I-Mab at the end of the most recent reporting period. Hedge funds and other institutional investors own 38.38% of the company’s stock.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial.